Genentech, Inc.

23andme, Inc.

Genetech, Inc.

Chingwei Vivian Lee

Germaine G Fuh

Patrick Koenig

Amin Famili

Karthikan Rajagopal

Yan Wu

Wei-Ching Liang

Robert F Kelley

Daniel Kirchhofer

Menno Van Lookeren Campagne

Tao Sai

Germaine Fuh-Kelly

Kelly M Loyet

Louise Scharf

Joyce Lai

Michael Terry Lipari

Tina Thai

Krista Maureen McCutcheon

Yu Chen

Shouhua Xiao

Yao-ming Huang

Anil Durgadas Bagri

Samuel Nalle

Navneet Singh

Zuoan Yi

Valentine Yeung

Augusta Eleanor Broughton

Michael T Lipari

Daniel K Kirchhofer

Mark S Dennis

Avi J Ashkenazi

Jo-Anne Hongo

Dorothy French

Gretchen Frantz

Erik E Karrer

Robert Maurice Pitti

Liliana Soroceanu

David A Eberhard

Beni B Wolf

Helga A Raab

Ashka Bharat Patel

Shashank Bharill

Heidi Ackerly

Scot A Masters

Evgeny Varfolomeev

David Eberhard

Scot Marsters

Helga Raab

Beni Wolf

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.

Anti-CD96 antibodies and methods of use thereof

The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Optimized variants of anti-VEGF antibodies

The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.

Dual specific antibodies for binding interleukin 4 (IL4) and interleukin 5 (IL5)

The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer

The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36α, IL-36β, and/or IL-36γ, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

Anti-IL-36 antibodies and methods of use thereof

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Anti-HtrA1 antibodies and methods of use thereof

Conjugates comprising a vascular endothelial growth factor (VEGF) antibody and a hyaluronic acid polymer

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Anti-CD3 antibodies and methods of use

Polynucleotides encoding optimized variants of anti-VEGF antibodies

Optimized variants of anti-vegf antibodies and methods of use thereof in treatment

The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

Dual specific antibodies

Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis

Growing community of inventors

Foster City, CA, United States of America

Chingwei Vivian Lee